New Triple-Threat treatment tested to shrink tough rectal tumors before surgery
NCT ID NCT07505472
Summary
This study is testing a new combination of treatments given before surgery for people with high-risk rectal cancer. The goal is to see if adding a drug called surufatinib to a standard regimen of short radiation, chemotherapy, and immunotherapy helps shrink tumors more effectively. Researchers will compare the two approaches in about 212 participants to find which is safer and leads to better outcomes, like being cancer-free after surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the first hospital of Jilin University
RECRUITINGChangchun, Jilin, 130000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.